Skip to content
Parakho

Dishman Carbogen Amcis Ltd

NSE DCALBSE 540701imdcal.com

Q1 FY27, unaudited

Revenue
₹57.08 Cr
Profit after tax
₹-23.91 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations57.08−9.20%231.56
Other income18.89−49.52%84.52
Total income75.97−24.24%316.08
Employee benefit expense21.05−5.52%86.63
Finance costs21.71+7.16%86.52
Depreciation & amortisation15.37−6.68%62.57
Total expenses105.98+10.21%375.33
Profit before tax-31.70−869.42%-59.25
Tax expense-7.79−637.24%-20.85
Profit after tax-23.91−995.51%-38.40
Total comprehensive income2.25+108.16%-148.26
Earnings per share
Earnings per share, basic₹-1.52₹-2.45
Earnings per share, diluted₹-1.52₹-2.45

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Dishman Carbogen Amcis reported a 4% year-on-year decline in Q1 FY27 revenue to INR 6,776 million, which management attributed largely to an order postponed to the second half of the year. EBITDA fell to INR 600 million from INR 1,406 million in the prior year quarter, with the CDMO segment margin dropping to 6.3% from 17.9%. Management discussed an in-progress plan to raise up to CHF 200 million via the promoter entity to refinance high-cost Indian debt, and outlined expectations of single-digit revenue growth for the full year with EBITDA margins similar to the prior year.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 52 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 08 Oct 2026.